As cancer risk rises exponentially with age and is the second leading cause of mortality in adult US population (CDC/NCHS National Vital Statistics System, 2010), reducing its incidence through inhibition of IGF-1 action may have a major impact on morbidity and mortality in the elderly. The gene discussed is IGF1; the disease is cancer.